Novartis Archives | PharmaShots

Novartis Voluntary Nationwide Recalls Three Lots of Promacta (eltrombopag, 12.5 mg) Oral Suspension Due to Peanut Contamination

May 13, 2019May 15, 2019Tuba Khan

Shots: Novartis recalls three lots of Promacta oral suspension to the consumer level due to the presence of peanut floor contamination occurred at [...]

Novartis Acquires Worldwide Rights of Takeda’s Xiidra (lifitegrast ophthalmic solution) for $5.3B

May 9, 2019May 10, 2019Tuba Khan

Shots: Takeda to receive $3.4B upfront with 1.9B milestones, making a total deal value of $5.3B. Novartis to get WW rights of Xiidra [...]

Novartis Reports Results of MS Progression Discussion Tool in a Validation Study for Patients with Multiple Sclerosis

May 7, 2019May 10, 2019Tuba Khan

Shots: The Validation study involves assessing of MSProDiscuss in 198 patients with relapsing-remitting MS (RRMS), secondary progressive MS (SPMS) or a suspected transition [...]

Novartis Reports Results of Zolgensma (onasemnogene abeparvovec-xioi) in P-III STR1VE Study for Spinal Muscular Atrophy (SMA) Type 1

April 17, 2019April 24, 2019Tuba Khan

Shots: The P-III STR1VE study involves assessing of Zolgensma in 22 patients with SMA Type1 + one or two copies of the SMN2 [...]

Novartis Reports Results of Entresto (sacubitril/valsartan) in PIONEER-HF 4-Week Extension Study for Systolic Heart Failure

March 18, 2019April 24, 2019Shiwani Sharma

Shots: The PIONEER-HF 4-week extension study involves assessing Entresto vs Enalapril in ~832 patients with systolic heart failure treated with Entresto for the [...]

Novartis

Novartis Voluntary Nationwide Recalls Three Lots of Promacta (eltrombopag, 12.5 mg) Oral Suspension Due to Peanut Contamination

Novartis Acquires Worldwide Rights of Takeda’s Xiidra (lifitegrast ophthalmic solution) for $5.3B

Novartis Reports Results of MS Progression Discussion Tool in a Validation Study for Patients with Multiple Sclerosis

Novartis Reports Results of Zolgensma (onasemnogene abeparvovec-xioi) in P-III STR1VE Study for Spinal Muscular Atrophy (SMA) Type 1

Novartis Reports FDA’s Acceptance of BLA for Brolucizumab (RTH258) to Treat Wet AMD

Novartis’ Cosentyx (secukinumab) Receives NMPA’s (CFDA) Approval for Patients with Plaque Psoriasis in Adults

Novartis to Acquire IFM Tre for its Clinical and Preclinical Portfolio of NLRP3 Inhibitors for $1.5B

Novartis’ Mayzent (siponimod) Receives FDA’s Approval for Patients with Secondary Progressive Multiple Sclerosis (SPMS)

Novartis Announces Spin-Off of Alcon Eye Care Business on April 9, 2019

Novartis Reports Results of Entresto (sacubitril/valsartan) in PIONEER-HF 4-Week Extension Study for Systolic Heart Failure